MARKET

AGRX

AGRX

Agile Therapeutics Inc
NASDAQ
0.3011
-0.0005
-0.17%
Opening 15:09 10/06 EDT
OPEN
0.3080
PREV CLOSE
0.3016
HIGH
0.3150
LOW
0.3000
VOLUME
585.02K
TURNOVER
118.47K
52 WEEK HIGH
39.58
52 WEEK LOW
0.2620
MARKET CAP
11.75M
P/E (TTM)
-0.0140
1D
5D
1M
3M
1Y
5Y
'West Virginia governor signs abortion ban, making state the second to enact abortion restrictions since Roe overturned.' - Tweet By Zeke Miller
https://twitter.com/ZekeJMiller/status/1570831511469060096
Benzinga · 09/16 17:48
BRIEF-Agile Therapeutics Received Nasdaq Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
BRIEF-Agile Therapeutics Received Nasdaq Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
Reuters · 08/19 20:43
BRIEF-Agile Therapeutics Reports Q2 Loss Per Share $2.71
BRIEF-Agile Therapeutics Reports Q2 Loss Per Share $2.71
Reuters · 08/11 21:35
-- Earnings Flash (AGRX) AGILE THERAPEUTICS Reports Q2 Revenue $2.1M, vs. Street Est of $1.98M
-- Earnings Flash (AGRX) AGILE THERAPEUTICS Reports Q2 Revenue $2.1M, vs. Street Est of $1.98M
MT Newswires · 08/11 16:34
Agile Therapeutics Q2 2022 Earnings Preview
Agile Therapeutics (NASDAQ:AGRX) is scheduled to announce Q2 ea...
Seekingalpha · 08/10 21:35
Agile Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on Thursday, August 11, 2022
Live Conference Call and Webcast at 4:30 p.m. ETPRINCETON, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report second quarter 2022 financial results after the market ...
GlobeNewswire · 07/28 12:05
Woman-Health Focused Stock Agile Therapeutics Is 'Better Positioned,' Analyst Says While Upgrading Stock
Maxim Group upgraded Agile Therapeutics Inc (NASDAQ: AGRX) to Buy from Hold with a price target of $1, saying it should be better positioned to begin to rebound. Agile recently closed an equity offering, raising around $24 million in gross proceeds, and br...
Benzinga · 07/26 19:47
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Benzinga · 07/26 12:14
More
About AGRX
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. The Company’s sole approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive. Twirla is a method of contraception for use in women of reproductive potential for whom a combined hormonal contraceptive is appropriate. Twirla is a prescription combined hormonal contraceptive patch, which contains the active ingredients ethinyl estradiol (EE), which is a synthetic estrogen and levonorgestrel (LNG), which is a type of progestin. Twirla delivers 30 micrograms of EE per day, a dose of EE consistent with the dose delivered by many commonly prescribed oral contraceptives. The Company commercializes Twirla in the United States. Twirla leverages the Company’s transdermal patch technology called Skinfusion. Skinfusion is designed to allow drug delivery through the skin while optimizing patch adhesion and patient comfort and wearability.

Webull offers kinds of Agile Therapeutics Inc stock information, including NASDAQ:AGRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGRX stock methods without spending real money on the virtual paper trading platform.